Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature
| العنوان: | Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature |
|---|---|
| المؤلفون: | Shota Yoshida, Makoto Ogasawara, Akane Shido, Akimitsu Meno, Takuto Miyagishima, Naoki Kawagishi, Satoshi Abiko, Itsuki Sano, Kazuaki Harada, Ayumu Yoshikawa, Ko Ebata, Sonoe Yoshida, Soichiro Oda, Hisashi Oda |
| المصدر: | Thoracic Cancer, Vol 11, Iss 5, Pp 1350-1353 (2020) Thoracic Cancer |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Case Report, Adenocarcinoma of Lung, Pembrolizumab, Case Reports, Immune checkpoint inhibitor, Antibodies, Monoclonal, Humanized, pericardial tamponade, Pericardial effusion, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, medicine, Humans, Stage (cooking), Lung cancer, business.industry, General Medicine, Middle Aged, medicine.disease, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Primary tumor, pericardial effusion, Surgery, Cardiac Tamponade, 030104 developmental biology, Oncology, Pericardiocentesis, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Tamponade, pembrolizumab, Neoplasm Recurrence, Local, business |
| الوصف: | Several studies have demonstrated increased pericardial effusion during anti‐PD‐1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial. In this study, we describe a 63‐year‐old woman with stage IVA lung adenocarcinoma given pembrolizumab as a first‐line therapy. After four cycles of pembrolizumab treatment, the patient suddenly developed a pericardial tamponade. Although pericardial effusion was increased, her tumor lesions were reduced. After an emergency pericardiocentesis, she continued the pembrolizumab therapy without recurrent pericardial effusions for three months until the primary tumor and lymph node metastasis progressed. Nine months after the pericardiocentesis, the patient died of progressive lung cancer, but pericardial effusion did not recur throughout the treatment course. This case study suggests that pembrolizumab therapy can be continued with a strict follow‐up in some patients with pembrolizumab‐induced pericardial tamponade. Key points • Significant findings of the study Our patient developed pericardial tamponade during pembrolizumab treatment but continued pembrolizumab treatment after emergency pericardiocentesis without recurrent pericardial effusions. • What this study adds Pembrolizumab treatments may be resumed with a strict follow‐up in some patients with treatment‐related pericardial tamponade. |
| اللغة: | English |
| تدمد: | 1759-7706 1759-7714 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f11c191ca8a08a8b3a2f1ac6e50df6 https://doaj.org/article/71c79c31b16a44a5aa306e598f2a22b5 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....92f11c191ca8a08a8b3a2f1ac6e50df6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597706 17597714 |
|---|